ALK rearrangements and resistance mutations in non-small cell lung cancer: molecular mechanisms and therapeutic implications.
Level 5 - mechanism / opinion, no new human data
Narrative review of molecular mechanisms and therapeutic resistance without systematic review methodology
PubMed 42371103 · doi:10.1007/s00280-026-04910-z
What was done
This paper reviews the molecular mechanisms of ALK gene rearrangements (predominantly EML4-ALK fusions) in non-small cell lung cancer (NSCLC), the activity of approved ALK inhibitors (crizotinib, ceritinib, alectinib, brigatinib, and lorlatinib), and the on-target and off-target mechanisms underlying acquired drug resistance.
What was found
The abstract reports no quantitative values or statistical effect sizes. It describes qualitative mechanisms of resistance: on-target resistance driven by conformational changes in the ATP-binding site from solvent-front and gatekeeper mutations (particularly G1202R-associated compound mutations), poorer prognosis and higher metastasis risk associated with EML4-ALK variant 3, and off-target resistance driven by bypass signaling pathway activation.
Why it matters
It outlines the structural and evolutionary drivers of tyrosine kinase inhibitor failure in ALK-positive NSCLC to highlight targets for next-generation inhibitors.
Limits
The abstract describes a narrative overview without systematic search parameters, quantitative meta-analysis, or primary clinical trial data.
Cited by
- supports Cancer cells frequently evolve resistance to targeted molecular therapies through secondary genetic mutations, analogous to bacterial antibiotic resistance.